Cargando…
Immune Cell Infiltration of the Primary Tumor, Not PD-L1 Status, Is Associated With Improved Response to Checkpoint Inhibition in Metastatic Melanoma
Immune checkpoint inhibition has resulted in dramatic improvements in overall and relapse-free survival in patients with metastatic melanoma. The most commonly used immune checkpoint inhibitors are monoclonal antibodies targeting programmed cell death protein 1 and cytotoxic T-lymphocyte-associated...
Autores principales: | Kümpers, Christiane, Jokic, Mladen, Haase, Ozan, Offermann, Anne, Vogel, Wenzel, Grätz, Victoria, Langan, Ewan A., Perner, Sven, Terheyden, Patrick |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6425878/ https://www.ncbi.nlm.nih.gov/pubmed/30931305 http://dx.doi.org/10.3389/fmed.2019.00027 |
Ejemplares similares
-
Sequential Treatment With Targeted and Immune Checkpoint Therapy in Patients With BRAF Positive Metastatic Melanoma: The Importance of Timing?
por: Grätz, Victoria, et al.
Publicado: (2019) -
The treatment of Merkel cell carcinoma with immune checkpoint inhibitors: implications for patients with rheumatoid arthritis
por: Klee, Gina, et al.
Publicado: (2021) -
Generalized morphoea in the setting of combined immune checkpoint inhibitor therapy for metastatic melanoma: A case report
por: Langan, Ewan A., et al.
Publicado: (2021) -
PD-L1 Dependent Immunogenic Landscape in Hot Lung Adenocarcinomas Identified by Transcriptome Analysis
por: Kirfel, Jutta, et al.
Publicado: (2021) -
Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid
por: Sadik, Christian D., et al.
Publicado: (2019)